Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> MutationRichard M. Stone, Hartmut Döhner, Francesco Lo‐Coco et al.|New England Journal of Medicine|2017Cited by 2.2k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemiaEytan M. Stein, Martin S. Tallman, Courtney D. DiNardo et al.|Blood|2017Cited by 1.5k
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaJeffrey E. Lancet, Bruno C. Medeiros|Journal of Clinical Oncology|2018Cited by 983
Genomic landscape of neutrophilic leukemias of ambiguous diagnosisHaijiao Zhang, Jeffrey Tyner, Beth Wilmot et al.|Blood|2019Cited by 84
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experienceArmon Azizi, Tian Yi Zhang, Asiri Ediriwickrema et al.|Leukemia & lymphoma/Leukemia and lymphoma|2020Cited by 29